Pemphigus and Bullous Pemphigoid Following COVID-19 Vaccination: A Systematic Review Authors: Fabrizio Martora, Teresa Battista, Luca Potestio, Maddalena Napolitano, Cataldo Patruno, Matteo Megna, Michela D’Agostino Published: 2024 ABSTRACT The COVID-19 pandemic has encouraged the rapid development and licensing of vaccines against SARS-CoV-2. Currently, numerous vaccines are available on a global scale and are based on different mechanisms of action, including mRNA technology, viral vectors, inactive viruses, and subunit particles. Mass vaccination conducted worldwide has highlighted the potential development of side effects, including ones with skin involvement. This review synthesizes data from 62 manuscripts, reporting a total of 142 cases of autoimmune blistering skin diseases (AIBDs) following COVID-19 vaccination, comprising 59 cases of pemphigus and 83 cases of bullous pemphigoid. Among the 83 bullous pemphigoid cases, 78 were BP, with additional cases including 2 oral mucous membrane pemphigoid, 1 pemphigoid gestationis, 1 anti-p200 BP, and 1 dyshidrosiform BP. The mean age of affected individuals was 72 ± 12.7 years, with an average symptom onset of 11 ± 10.8 days post-vaccination. Notably, 59% of cases followed vaccination with BNT162b2 (Pfizer-BioNTech), 51.8% were new diagnoses, and 45.8% occurred after the second dose. The purpose of our review is to analyze the cases of pemphigus and bullous pemphigoid associated with COVID-19 vaccination and to investigate the pathogenetic mechanisms underlying the new development or flare-up of these diseases in association with vaccination. Our results show that the association between COVID-19 vaccines and AIBDs is a possible event. 1. Introduction Mucocutaneous adverse events have emerged as some of the most frequently reported reactions associated with COVID-19 vaccination, drawing considerable attention from the medical community. These reactions encompass a broad spectrum of clinical presentations, which can be classified into various categories depending on the underlying pathogenetic mechanisms. These mechanisms include hypersensitivity reactions, notably types I and IV, which involve immediate and delayed immune responses, respectively. Additionally, local site reactions at the injection site, autoimmune-mediated reactions, functional angiopathies, and the reactivation of latent viral conditions have been identified as potential contributors to these adverse skin manifestations following the administration of COVID-19 vaccines [1,2]. Within the broader scope of autoimmune diseases, there has been a notable increase in reports of new onset or recurrence of autoimmune bullous diseases (AIBDs) following COVID-19 vaccination. These diseases, characterized by the formation of blisters on the skin and mucous membranes, are particularly concerning due to their chronic nature and the significant impact they have on patients’ quality of life [3]. Among the various types of AIBD, pemphigus and bullous pemphigoid (BP) are the most prominent, each with distinct pathophysiological features. Pemphigus is characterized by the presence of autoantibodies directed against desmosomes, the structures that facilitate cell-to-cell adhesion within the epidermis, leading to intraepidermal blistering. In contrast, BP involves autoantibodies targeting hemidesmosomes, which anchor the epidermis to the underlying basement membrane, resulting in subepidermal blistering. Given the increasing number of reported cases, there is a pressing need to understand the potential relationship between COVID-19 vaccination and the onset or exacerbation of these diseases. The aim of our study was to conduct a comprehensive review of the recent literature focusing on cases of new diagnoses and flare-ups of pemphigus and BP following COVID-19 vaccination. By examining these cases, we seek to elucidate any patterns or trends that may contribute to a better understanding of the potential risks associated with COVID-19 vaccines in relation to these serious autoimmune conditions [4]. 2. Methods Comprehensive literature research was conducted on MEDLINE/PubMed, Web of Science, embase, scopus, and Google Scholar databases until May 2024. The following keywords were used to research data: “bullous pemphigoid”, “pemphigus”, “pemphigus vulgaris (PV”), “pemphigus foliaceus (PF)”, “autoimmune bullous disease”, “immune-mediated inflammatory disease”, “COVID-19”, “vaccination”, “vaccine”, “skin manifestations”, “adverse events”, “Pfizer/BioNTech”, “BNT162b2”, “Moderna”, “mRNA-1273”, “AstraZeneca”, “AZD1222”, “Covishield”, “Johnson & Johnson”, “Ad26.COV2.S”, “BBIBP-CorV”, “Sinopharm”, “CoronaVac”, “mRNA”, “viral-vector”, “cutaneous”, “side effect”. Data from the selected case reports and case series were analyzed, and a total of 62 articles were found to be relevant. The references of the selected manuscripts were evaluated to include articles that could have been missed. Our analysis included EMA-approved vaccines, and the main vaccines spread globally. The selection and extraction of relevant data followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines (Figure 1). 2.1. Study Selection In the first step, two researchers (M.D. and F.M.) reviewed the retrieved articles and removed the duplicates. In other steps, the researchers screened the title and abstract of the records, and the ineligible studies were removed. Then, the authors surveyed the full text of the remaining studies based on inclusion and exclusion criteria, and the eligible studies were identified. We decided to exclude certain articles based on the following criteria: articles that were not original research, such as reviews or editorials; articles for which the full text was unavailable; papers that were only available as abstracts, including conference abstracts; clinical trials that were still ongoing and had not yet published results; articles written in languages other than English. 2.2. Risk of Bias Selection The quality of enrolled studies was appraised by two investigators (F.M. and T.B) using the revised Cochrane risk-of-bias tool for letter to editor, case report, case series, and reviews. Through evaluating the methodology, the overall risk of bias was judged as low, high, or of some concern. If differing opinions existed, the third author (M.M.) was consulted for arbitration. 3. Result Data resulting from the 62 reviewed manuscripts are synthesized in Table 1. A total of 59 cases of pemphigus and 83 of BP following COVID-19 vaccination were collected, amounting to a total of 142 cases of autoimmune blistering skin diseases (AIBDs). Data on the vaccination dose and the time to onset the symptoms refer to the last dose of vaccine administered before the onset of clinical manifestations. Data on registered cases of BP are reported in Table 2. A total of 83 cases of pemphigoid were registered, including 78 BP cases, 2 oral mucous membrane pemphigoid cases, 1 case of pemphigoid gestationis, 1 case of anti-p200 BP, and 1 case of dyshidrosiform BP. Among these, 46 cases involved the male population (55.42%). The mean age was 72 ± 12.7, while the average time of onset of symptoms was 11 ± 10.8 days. Most cases occurred following vaccination with BNT162b2 (Pfizer-BioNTech) [49, (59%)]. The new diagnoses were 43 (51.8%), and pemphigoid cases occurred mainly after the administration of the second dose [38 (45.8%)]. Data on registered cases of pemphigus are reported in Table 3. A total of 59 cases of pemphigus were registered, including 33 cases of PV, 19 cases of PF, 1 case of pemphigus vegetans, 1 case of pemphigus erythematosus, 1 case of oral pemphigus, 1 case of IgA pemphigus, and 3 cases of an unspecified subtype of pemphigus. The mean age was 55 ± 16.6, while the average time of onset of symptoms was 14 ± 11.7 days from the last vaccination. The female population was involved in a higher percentage [34, (57.6%)]. Most cases developed as a result of vaccinations with BNT162b2 (Pfizer-BioNTech) [29, (49.2%)] and mainly after the administration of the second dose [24, (40.7%)]. 4. Discussion Bullous pemphigoid (BP) is an autoimmune blistering disease involving autoantibodies against BP180 and BP230 proteins in the basement membrane. Triggers include UV radiation, trauma, drugs, malignancies, and vaccinations. Cases have been associated with vaccines for influenza, tetanus, diphtheria, polio, pertussis, meningococcal disease, pneumococcal disease, hepatitis B, and rabies. Pemphigus, another autoimmune disorder affecting the skin and mucous membranes, can also be triggered by infections, radiation, drugs, vaccines, pregnancy, or stress, particularly in genetically predisposed individuals. Vaccines such as those for influenza, hepatitis B, rabies, and tetanus have been reported to trigger or exacerbate the disease [65,66,67,68,69,70,71,72]. It is well-established that vaccinations and infections can exacerbate autoimmune diseases, including after COVID-19 vaccines [73,74,75,76,77,78,79,80,81,82,83,84,85]. Numerous new-onset autoimmune diseases, such as systemic lupus erythematosus, Guillain-Barré syndrome, autoimmune liver diseases, and rheumatoid arthritis, have been reported post-COVID-19 vaccination. Among autoimmune skin conditions, cases of vitiligo, alopecia areata, lupus, pityriasis rosea, herpes zoster, leukocytoclastic vasculitis, and autoimmune blistering diseases (AIBD) have also been noted in a systematic review by Ghanaatpisheh et al. [86]. BP and pemphigus can be triggered by environmental factors stimulating autoimmunity in susceptible individuals. COVID-19 vaccines may contribute through mechanisms such as epitope spreading, molecular mimicry, and bystander activation. A systematic review suggests that molecular mimicry between the spike protein and basement membrane components, like BP230 and BP180, could lead to autoantibody production. Vaccination also strongly activates T-helper lymphocytes, cytokine production, autoantibody generation, and complement pathway activation, causing basement membrane damage. Pemphigus cases post-vaccination are similarly linked to mechanisms like molecular mimicry and bystander activation, with a potential role for CD8+ lymphocytes and the Fas/FasL pathway [33]. Our findings show an increased number of BP and pemphigus cases following mRNA vaccines, particularly BNT162b2, consistent with other studies [78,79,80,81,82,83,84,85,86,87]. There are cases in the literature to report regarding the occurrence or exacerbation of pemphigus following other vaccines. Regarding PV, Cozzani et al. reported a case of pemphigus vulgaris (PV) that developed following tetanus and diphtheria vaccination in an 11-year-old girl. Additionally, Berkun et al. and Mignogna et al. documented two separate instances of PV occurring after vaccination, with one emerging 3 months post-hepatitis B vaccination and the other 1 month after receiving the influenza vaccine [88,89,90]. Other cases are reported as exacerbation of pre-existing PV after influenza vaccination [91]. A different discussion exists for BP because there are no definite and reported data of association in the literature but only reports mostly in pediatric age following the combination of various vaccines. Therefore, with respect to PV, it is not possible to correlate it with one type of vaccine [92,93,94,95]. The mechanisms that cause relapse after vaccination remain uncertain. Two main hypotheses have been proposed: (i) an overactive immune response in individuals with a genetic predisposition, possibly leading to the development of anti-desmoglein antibodies, and (ii) cross-reactivity between vaccine antigens and pemphigus antigens. While there is no definitive evidence supporting these theories in pemphigus or other immune-mediated blistering conditions, such mechanisms have been suggested in the vaccine-induced worsening of other autoimmune diseases [96]. Influenza vaccination is generally recommended for patients on immunosuppressive therapy; however, it may trigger a flare-up of the underlying disease in individuals receiving treatment for autoimmune disorders [96,97,98,99,100]. As reported for COVID-19 vaccination, we can certainly say that although the association may also be present with other vaccines, the benefit of the vaccine itself far outweighs the risk of both occurrence and exacerbation. 5. Conclusions COVID-19 vaccines were developed to overcome the pandemic period, and the mass administration of such vaccines has led to adverse reactions not often detected in clinical trials. The association between COVID-19 vaccines and AIBD is a possible event. However, the exact correlation between the development of bullous diseases and vaccine administration requires clarification and needs further investigation. The identification of a potential causal relationship between vaccination and the occurrence or recurrence of these diseases is important for assessing the risk and counseling patients.